Therapeutic Applications for MASLD/MASH @American_Heart
Therapeutic Applications for MASLD/MASH  @American_Heart
Uploaded October 2026 | Updated November 2026, 1 day ago
Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are rapidly increasing in prevalence, driven by rising rates of obesity, insulin resistance, and other metabolic risk factors. Faculty will review the physiological roles of glucagon and incretin receptor signaling and explain how emerging therapies modulate these pathways to improve liver and cardiometabolic outcomes. Join this program to stay current and gain practical guidance to help improve the care of patients with MASLD/MASH.
Multiple CE credit types available: bit.ly/MASLD_MASH
Therapeutic Applications for MASLD/MASH2025-26 Hearts on the Court Collective: Coach Molly Miller of Arizona StateWant to live longer and better? Heres how moving your body can helpThe Power of Impact InvestingBorn with a Special Heart: Everlys Story of Strength and HopeWhat is a Color Walk?4 Hidden Perks in Your Health Plan You May Be Missing | Health Benefits BasicsA doctors tips for managing cholesterolJoin the American Heart Association Support NetworkDoes estrogen affect stroke risk? What the experts say.American Heart Association PREVENT™ Equations: OverviewAmerican Heart Association | Kids Heart Challenge | Meet Beacon
American Heart Association |

Therapeutic Applications for MASLD/MASH

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER